Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

BliNK Biomedical

BliNK Biomedical
2014 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Series A LATEST DEAL TYPE
$1.84M LATEST DEAL AMOUNT
4 INVESTORS
Description

Developer of a cell technology created to treat life threatening diseases. The company's technology offer antibody-based therapeutics that targets an immune checkpoint causing an immune switch to renders tumors susceptible to the body's immune system and constitute a highly efficient and deep mining process that provides an unprecedented capability to identify very rare antibody-secreting cells from human and non-human species, enabling users to be able to address a number of attractive, novel immuno-oncology and immune-checkpoint targets.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • Gerland Plaza Techsud
  • 70, rue Saint-Jean-de-Dieu
  • 69007 Lyon
  • France
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore BliNK Biomedical’s full profile, request a free trial.

BliNK Biomedical Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 12-Jul-2016 $1.84M 00.000 Completed Generating Revenue
1. Early Stage VC (Series A) 11-Dec-2014 00.000 00.000 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

BliNK Biomedical Competitors (47)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
000000000 Venture Capital-Backed Vancouver, Canada 00 0000 00000000000 0000
0000 000000 Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
000000000 Venture Capital-Backed Rockville, MD 000.00 0000000000 0 000.00
0000000 0000000000 Venture Capital-Backed La Jolla, CA 00000 00000000000 00000
To view this company’s complete list of competitors, request access »

BliNK Biomedical Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Cancer Research UK Venture Capital Minority 000 0000 000000 0
Idinvest Partners Venture Capital Minority 000 0000 000000 0
Kurma Partners Venture Capital Minority 000 0000 000000 0
Valneva Corporation Minority 000 0000 000000 0

BliNK Biomedical Executive Team (2)

Name Title Board
Seat
Contact
Info
Jack Elands Ph.D Chief Executive Officer & Board Member
Nicola Beltraminelli Ph.D Chief Scientific Officer

BliNK Biomedical Board Members (8)

Name Representing Role Since Contact
Info
Franck Grimaud Valneva Board Member 000 0000
Frederic Legros BliNK Biomedical Board Member 000 0000
Irina Staatz Self Chairman 000 0000
Jack Elands Ph.D BliNK Biomedical Chief Executive Officer & Board Member 000 0000
Klaus Schwamborn Ph.D Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »